ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Final Approval for Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation). Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) on 3rd March, 2021 as per the attached file. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the registered shareholder(s) in English language newspaper - Business Standard on 23rd February, 2021. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) on 18th February, 2021 as per the enclosed details. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's wholly-owned subsidiary, Alembic Global Holding SA, has received US Food & Drug Administration (USFDA) Final Approval for Treprostinil Injection, 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), Multiple-Dose Vials. Please find enclosed herewith our press release. We request you to kindly take the same on record.
Novel blood cancer drug developed by Alembic Pharma's associate Rhizen gets US approval
Umbralisib has peak market size potential to reach $1 billion - $1.5 billion ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Our Associate Company, Rhizen Pharmaceuticals AG ('Rhizen') has issued a Press Release announcing that its Partnered Asset, Umbralisib (UKONIQTM) has received United States Food and Drug Administration (USFDA) Accelerated Approval for Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL). Please find enclosed herewith Rhizen's press release. Alembic Pharmaceuticals Limited through its wholly owned subsidiary holds 50% ownership in Rhizen. We request you to kindly take the same on record.
Alembic Pharma gets five observations from USFDA for Gujarat facility
"The United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals'' New Injectable Facility (F-3) located at Karkhadi from January 29-February 5, 2021. ALEMBIC PHARMACEUTICALS LTD. - 533573 - USFDA Inspection At Alembic Pharmaceuticals New Injectable Facility (F-3) At Karkhadi
We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' New Injectable Facility (F-3) located at Karkhadi from 29th January 2021 to 6th February 2021. This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with 5 observations. None of the observations are related to data integrity and are procedural in nature. The Company is preparing the response to the observations, which will be submitted to USFDA shortly. The Company is committed to maintain highest quality standards that meet USFDA standards. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) and / or their legal heir(s) of such lost share certificate have requested the Company for issue of duplicate share certificate. We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company.